| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | crizotinib (Xalkori®) |
| Formulation | 200 mg, 250 mg capsule |
| Reference number | 2899 |
| Indication | First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/03/2016 |
| NICE guidance | |